awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q30313260-1CBEC5E2-95C1-43A6-98AE-5692F7393EEF
Q30313260-1CBEC5E2-95C1-43A6-98AE-5692F7393EEF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30313260-1CBEC5E2-95C1-43A6-98AE-5692F7393EEF
Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia.
P2860
Q30313260-1CBEC5E2-95C1-43A6-98AE-5692F7393EEF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30313260-1CBEC5E2-95C1-43A6-98AE-5692F7393EEF
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
3bea7eb090d70ec7d01d979d3203204e43e798e8
P2860
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.